Valproate (valproic acid, VPA, sodium valproate, and valproate semisodium forms) are medications primarily used to treat epilepsy and as a mood stabilizer in the treatment of bipolar disorder.[4] They are useful for the prevention of seizures in those with absence seizures, partial seizures, and generalized seizures.[4] They can be given intravenously or by mouth, and the tablet forms exist in both long- and short-acting formulations.[4]
Common side effects of valproate include nausea, vomiting, somnolence, and dry mouth.[4] Serious side effects can include liver failure, and regular monitoring of liver function tests is therefore recommended.[4] Other serious risks include pancreatitis and an increased suicide risk.[4]
Valproate is known to cause serious abnormalities or birth defects in the fetus if taken during pregnancy,[4][5] and is contra-indicated for women of childbearing age unless the drug is essential to their medical condition and the person is also prescribed a contraceptive.[4][6] Reproductive warnings have also been issued for men using the drug.[7]
Valproate is restricted in the United Kingdom for both women and men under age 55 due to teratogenicity in pregnant women and fertility problems in men. It is also restricted in the European Union.[8][9] The United States Food and Drug Administration has indicated a black box warning given the frequency and severity of the side effects and teratogenicity. Additionally, there is also a black box warning due to risk of hepatotoxicity and pancreatitis.[10]
Valproate has been in use in Japan for the prophylaxis of migraine since 2011.[11] It is approved as an antimanic and antiseizure in Japan as well.[12] In UK, valproate is approved for bipolar mania and epilepsy, and both valproate and divalproex are approved, although divalproex sodium[13] is known as valproate semisodium.[14]
Valproate's precise mechanism of action is unclear.[4][15] Proposed mechanisms include affecting GABA levels, blocking voltage-gated sodium channels, inhibiting histone deacetylases, and increasing LEF1.[16][17][18] Valproic acid is a branched short-chain fatty acid (SCFA), a derivative of valeric acid.[16]
Valproate was originally synthesized in 1881 and came into medical use in 1962.[19] It is on the World Health Organization's List of Essential Medicines.[20] It is available as a generic medication.[4] In 2023, it was the 160th most commonly prescribed medication in the United States, with more than 3million prescriptions.[21][22]
Medical uses
Valproate or valproic acid is used primarily to treat epilepsy and bipolar disorder.
Epilepsy
Valproate has a broad spectrum of anticonvulsant activity, although it is primarily used as a first-line treatment for tonic–clonic seizures, absence seizures and myoclonic seizures and as a second-line treatment for partial seizures and infantile spasms.[23] It has also been successfully given intravenously to treat status epilepticus.[24][25]
In the US, valproic acid is also prescribed as an anti-epileptic drug indicated for the treatment of manic episodes associated with bipolar disorder; monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in people with multiple seizure types that include absence seizures.[26]
Psychiatric disorders
Valproate products are used to treat manic or mixed episodes of bipolar disorder.[27][28]
A 2016 systematic review compared the efficacy of valproate as an add-on for people with schizophrenia:[29]
Other uses
Based upon five case reports, valproic acid may have efficacy in controlling the symptoms of the dopamine dysregulation syndrome that arise from the treatment of Parkinson's disease with levodopa.[30][31][32]
Valproate is not commonly used to prevent or treat migraine headaches, but it may be prescribed if other medications are not effective.[33]
The medication has been tested in the treatment of AIDS and cancer, owing to its histone-deacetylase-inhibiting effects. It has cardioprotective, kidney protective, antiinflammatory, and antimicrobial effects.[34]
Contraindications
Contraindications include:
- Pre-existing acute or chronic liver dysfunction or family history of severe liver inflammation (hepatitis), particularly medicine related.[35]
- Pregnancy 11% risk of birth defects and 30-40% risk of neuro-developmental disabilities which can be permanent[36]
- Known hypersensitivity to valproate or any of the ingredients used in the preparation[35]
- Urea cycle disorders[35]
- Hepatic porphyria[35]
- Hepatotoxicity[35]
- Mitochondrial disease[35]
- Pancreatitis[35]
- Porphyria[37]
Adverse effects
Most common adverse effects include:[38]
Serious adverse effects include:[38]
Valproic acid has a black box warning for hepatotoxicity, pancreatitis, and fetal abnormalities.[38]
There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height.[39][40][41] Valproic acid can also cause mydriasis, a dilation of the pupils.[42] There is evidence that shows valproic acid may increase the chance of polycystic ovary syndrome (PCOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PCOS is higher in women with epilepsy compared to those with bipolar disorder.[43] Weight gain is also possible.[44] Valproic acid may decrease platelets in proportion to its dosage, particularly in women and the elderly.[45]
- Nausea (22%)
- Drowsiness (19%)
- Dizziness (12%)
- Vomiting (12%)
- Weakness (10%)
- Bleeding
- Low blood platelets
- Encephalopathy
- Suicidal behavior and thoughts
- Low body temperature
Pregnancy
Valproate is a teratogen.[46] Teratogens can cause birth defects. Valproate is restricted for all women under age 55 in the United Kingdom and European Union. It has a black box warning for pregnancy in the United States.[47]
There are also restrictions for men. Children fathered by men taking valproate have a higher risk of neurodevelopmental disorders. Valproate is restricted for men under age 55 in the United Kingdom and European Union. The restrictions require two specialists to agree that there is no other effective or tolerated treatment for the patient.[48]
Elderly
Valproate may cause increased somnolence in the elderly. In a trial of valproate in elderly patients with dementia, a significantly higher portion of valproate patients had somnolence compared to placebo. In approximately one-half of such patients, there was associated reduced nutritional intake and weight loss.[38]
Overdose and toxicity
Excessive amounts of valproic acid can result in somnolence, tremor, stupor, respiratory depression, coma, metabolic acidosis, and death. In general, serum or plasma valproic acid concentrations are in a range of 20–100 mg/L during controlled therapy, but may reach 150–1500 mg/L following acute poisoning. Monitoring of the serum level is often accomplished using commercial immunoassay techniques, although some laboratories employ gas or liquid chromatography.[51] In contrast to other antiepileptic drugs, at present there is little favorable evidence for salivary therapeutic drug monitoring. Salivary levels of valproic acid correlate poorly with serum levels, partly due to valproate's weak acid property (pKa of 4.9).[52]
In severe intoxication, hemoperfusion or hemofiltration can be an effective means of hastening elimination of the drug from the body.[53][54] Supportive therapy should be given to all patients experiencing an overdose and urine output should be monitored.[38] Supplemental L -carnitine is indicated in patients having an acute overdose[55][56] and also prophylactically[55] in high risk patients. Acetyl- L -carnitine lowers hyperammonemia less markedly[57] than L -carnitine.
Interactions
Valproate inhibits CYP2C9, glucuronyl transferase, and epoxide hydrolase and is highly protein bound and hence may interact with drugs that are substrates for any of these enzymes or are highly protein bound themselves.[35] It may also potentiate the CNS depressant effects of alcohol.[35] It should not be given in conjunction with other antiepileptics due to the potential for reduced clearance of other antiepileptics (including carbamazepine, lamotrigine, phenytoin and phenobarbitone) and itself.[35] It may also interact with:[38][35][58]
- Aspirin: may increase valproate concentrations. May also interfere with valproate's metabolism.
- Benzodiazepines: may cause CNS depression and there are possible pharmacokinetic interactions.
- Carbapenem antibiotics: reduce valproate levels, potentially leading to seizures.
- Cimetidine: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
- Erythromycin: inhibits valproate's metabolism in the liver, leading to increased valproate concentrations.
- Ethosuximide: valproate may increase ethosuximide concentrations and lead to toxicity.
- Felbamate: may increase plasma concentrations of valproate.
- Mefloquine: may increase valproate metabolism combined with the direct epileptogenic effects of mefloquine.
- Oral contraceptives: may reduce plasma concentrations of valproate.
- Primidone: may accelerate metabolism of valproate, leading to a decline of serum levels and potential breakthrough seizure.
- Rifampicin: increases the clearance of valproate, leading to decreased valproate concentrations.
- Warfarin: valproate may increase free warfarin concentration and prolong bleeding time.
- Zidovudine: valproate may increase zidovudine serum concentration and lead to toxicity.
Pharmacology
Pharmacodynamics
Although the mechanism of action of valproate is not fully understood,[35] traditionally, its anticonvulsant effect has been attributed to the blockade of voltage-gated sodium channels and increased brain levels of the inhibitory synaptic neurotransmitter gamma-aminobutyric acid (GABA).[35] The GABAergic effect is also believed to contribute towards the anti-manic properties of valproate.[35] In animals, sodium valproate raises cerebral and cerebellar levels of GABA, possibly by inhibiting GABA degradative enzymes, such as GABA transaminase, succinate-semialdehyde dehydrogenase and by inhibiting the re-uptake of GABA by neuronal cells.[35] Prevention of neurotransmitter-induced hyperexcitability of nerve cells via Kv7.2 channel and AKAP5 may also contribute to its mechanism.[59] Valproate has been shown to protect against a seizure-induced reduction in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) as a potential therapeutic mechanism.[60]
Valproate is a histone deacetylase inhibitor. By inhibition of histone deacetylase, it promotes more transcriptionally active chromatin structures, that is it exerts an epigenetic effect. This has been proven in mice: Valproic acid induced histone hyperacetylation had brain function effects on the next generation of mice through changes in sperm DNA methylation.[61] Intermediate molecules include VEGF, BDNF, and GDNF.[62][63]
Endocrine actions
Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels.[64] In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations.[65] These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment.[64][65]
Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men.[66][67] High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid.[67]
Endocrine actions
Valproic acid has been found to be an antagonist of the androgen and progesterone receptors, and hence as a nonsteroidal antiandrogen and antiprogestogen, at concentrations much lower than therapeutic serum levels.[64] In addition, the drug has been identified as a potent aromatase inhibitor, and suppresses estrogen concentrations.[65] These actions are likely to be involved in the reproductive endocrine disturbances seen with valproic acid treatment.[64][65]
Valproic acid has been found to directly stimulate androgen biosynthesis in the gonads via inhibition of histone deacetylases and has been associated with hyperandrogenism in women and increased 4-androstenedione levels in men.[66][67] High rates of polycystic ovary syndrome and menstrual disorders have also been observed in women treated with valproic acid.[67]
Pharmacokinetics
Taken by mouth, valproate is rapidly and virtually completely absorbed from the gut.[68] When in the bloodstream, 80–90% of the substance are bound to plasma proteins, mainly albumin. Protein binding is saturable: it decreases with increasing valproate concentration, low albumin concentrations, the patient's age, additional use of other drugs such as aspirin, as well as liver and kidney impairment.[70][71] Concentrations in the cerebrospinal fluid and in breast milk are 1 to 10% of blood plasma concentrations.[68]
The vast majority of valproate metabolism occurs in the liver. Valproate is known to be metabolized by the cytochrome P450 enzymes CYP2A6, CYP2B6, CYP2C9, and CYP3A5. It is also known to be metabolized by the UDP-glucuronosyltransferase enzymes UGT1A3, UGT1A4, UGT1A6, UGT1A8, UGT1A9, UGT1A10, UGT2B7, and UGT2B15. Some of the known metabolites of valproate by these enzymes and uncharacterized enzymes include (see image): All in all, over 20 metabolites are known.[68]
In adult patients taking valproate alone, 30–50% of an administered dose is excreted in urine as the glucuronide conjugate. The other major pathway in the metabolism of valproate is mitochondrial beta oxidation, which typically accounts for over 40% of an administered dose. Typically, less than 20% of an administered dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose of valproate is excreted unchanged (i.e., as valproate) in urine.[72] Only a small amount is excreted via the faeces.[68] Elimination half-life is 16±3 hours and can decrease to 4–9 hours when combined with enzyme inducers.[68][71]
- via glucuronidation (30–50%): valproic acid β-O-glucuronide
- via beta oxidation (>40%): 2E-ene-valproic acid, 2Z-ene-valproic acid, 3-hydroxyvalproic acid, 3-oxovalproic acid
- via omega oxidation: 5-hydroxyvalproic acid, 2-propyl-glutaric acid
- some others: 3E-ene-valproic acid, 3Z-ene-valproic acid, 4-ene-valproic acid, 4-hydroxyvalproic acid
Chemistry
Valproic acid is a branched short-chain fatty acid and the 2-n-propyl derivative of valeric acid.[16]
History
Valproic acid was first synthesized in 1882 by Beverly S. Burton as an analogue of valeric acid, found naturally in valerian.[73] Valproic acid is a carboxylic acid, a clear liquid at room temperature. For many decades, its only use was in laboratories as a "metabolically inert" solvent for organic compounds. In 1962, the French researcher Pierre Eymard serendipitously discovered the anticonvulsant properties of valproic acid while using it as a vehicle for a number of other compounds that were being screened for antiseizure activity. He found it prevented pentylenetetrazol-induced convulsions in laboratory rats.[74] It was approved as an antiepileptic drug in 1967 in France and has become the most widely prescribed antiepileptic drug worldwide.[75] Valproic acid has also been used for migraine prophylaxis and bipolar disorder.[76]
Society and culture
Valproate is available as a generic medication.[4]
Restrictions
In 2024, for those under age 55, additional restrictions for valproate prescription have been imposed in the United Kingdom.[77] Patients under 55 can still receive valproate, but need to obtain the permission of two specialists. The restrictions are, in women, due to the potential for birth defects in children born of women of childbearing age. In men, the restrictions are due to the potential for reversible male infertility, testicular problems, and the risks of neurodevelopmental conditions in children born to men taking valproate in the 3 months before conception.[78][79] Similar restrictions have been imposed in the European Union for both women and men.[8][9][80] In February 2026, a French man, Jean-Marc Laurent, filed what has been described as the first legal complaint related to paternal exposure to valproate, alleging that his child developed neurodevelopmental disorders after he had been treated with the drug prior to conception.[81][82]
Approval status
Off-label uses
In 2012, pharmaceutical company Abbott paid $1.6 billion in fines to US federal and state governments for illegal promotion of off-label uses for Depakote, including the sedation of elderly nursing home residents.[114][115]
Some studies have suggested that valproate may reopen the critical period for learning absolute pitch and possibly other skills such as language.[116][117]
Formulations
Valproate exists in two main molecular variants: sodium valproate and valproic acid without sodium (often implied by simply valproate). A mixture between these two is termed semisodium valproate. It is unclear whether there is any difference in efficacy between these variants, except from the fact that about 10% more mass of sodium valproate is needed than valproic acid without sodium to compensate for the sodium itself.[120] In Europe, the US, and many other countries three variants of valproate are sold: valproic acid, sodium valproate and valproate semisodium also known as divalproex sodium, the latter is believed to have fewer gastrointestinal side-effects.[14][121] Divalproex sodium tablets are a formulation comprising valproate sodium and valproic acid in a 1:1 molar relationship.
Terminology
Valproate is a negative ion. The conjugate acid of valproate is valproic acid (VPA). Valproic acid is fully ionized into valproate at the physiologic pH of the human body, and valproate is the active form of the drug. Sodium valproate is the sodium salt of valproic acid. Divalproex sodium is a coordination complex composed of equal parts of valproic acid and sodium valproate.[124]
Brand names of valproic acid
Branded products include:
- Absenor (Orion Corporation Finland)
- Convulex (G.L. Pharma GmbH Austria)
- Depakene (Abbott Laboratories in US and Canada)[125]
- Depakin (Sanofi S.R.L. Italy)[126]
- Depakine (Sanofi Aventis France)
- Depakine (Sanofi Synthelabo Romania)
- Depalept (Sanofi Aventis Israel)
- Deprakine (Sanofi Aventis Finland)
- Encorate (Sun Pharmaceuticals India)
- Epilim (Sanofi Synthelabo Australia and South Africa)
- Stavzor (Noven Pharmaceuticals Inc.)
- Valcote (Abbott Laboratories Argentina)
- Valpakine (Sanofi Aventis Brazil)
- Orfiril (Desitin Arzneimittel GmbH Norway)
Brand names of sodium valproate
Portugal
- Tablets – Diplexil-R by Bial.
United States
- Intravenous injection – Depacon by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories. (Note: Depakene capsules are valproic acid).
- Depakote tablets are a mixture of sodium valproate and valproic acid.
- Tablets – Eliaxim by Bial.
Australia
New Zealand
All the above formulations are Pharmac-subsidised.[128]
- Epilim by Sanofi-Aventis
UK
- Depakote Tablets (as in USA)
- Tablets – Orlept by Wockhardt and Epilim by Sanofi
- Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
- Syrup – Epilim by Sanofi-Aventis
- Intravenous injection – Epilim Intravenous by Sanofi
- Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
- Enteric-coated tablets – Epilim EC200 by Sanofi is a 200 mg sodium valproate enteric-coated tablet.
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden
- Tablets – Orfiril by Desitin Pharmaceuticals
- Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa
- Syrup – Convulex by Byk Madaus[129]
- Tablets – Epilim by Sanofi-synthelabo
Malaysia
- Tablets – Epilim (200 ENTERIC COATED) by Sanofi-Aventis
- Controlled release tablets – Epilim Chrono (500 CONTROLLED RELEASE) by Sanofi-Aventis[130]
Romania
- Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
- Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
Canada
- Intravenous injection – Epival or Epiject by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories its generic formulations include Apo-Valproic and ratio-Valproic.
Japan
- Tablets – Depakene by Kyowa Hakko Kirin
- Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
- Syrup – Depakene by Kyowa Hakko Kogyo
Europe
In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.
Taiwan
- Tablets (white round tablet) – Depakine by Sanofi Winthrop Industrie (France)
Iran
- Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
- Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)
Israel
Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.
India, Russia and CIS countries
- Valparin Chrono by Sanofi India
- Valprol CR by Intas Pharmaceutical (India)
- Encorate Chrono by Sun Pharmaceutical (India)
- Serven Chrono by Leeven APL Biotech (India)
Uruguay
- Tablets – DI DPA by Megalabs
Portugal
- Tablets – Diplexil-R by Bial.
United States
- Intravenous injection – Depacon by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories. (Note: Depakene capsules are valproic acid).
- Depakote tablets are a mixture of sodium valproate and valproic acid.
- Tablets – Eliaxim by Bial.
Australia
New Zealand
All the above formulations are Pharmac-subsidised.[128]
- Epilim by Sanofi-Aventis
UK
- Depakote Tablets (as in USA)
- Tablets – Orlept by Wockhardt and Epilim by Sanofi
- Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
- Syrup – Epilim by Sanofi-Aventis
- Intravenous injection – Epilim Intravenous by Sanofi
- Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
- Enteric-coated tablets – Epilim EC200 by Sanofi is a 200 mg sodium valproate enteric-coated tablet.
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden
- Tablets – Orfiril by Desitin Pharmaceuticals
- Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa
- Syrup – Convulex by Byk Madaus[129]
- Tablets – Epilim by Sanofi-synthelabo
Malaysia
- Tablets – Epilim (200 ENTERIC COATED) by Sanofi-Aventis
- Controlled release tablets – Epilim Chrono (500 CONTROLLED RELEASE) by Sanofi-Aventis[130]
Romania
- Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
- Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
Canada
- Intravenous injection – Epival or Epiject by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories its generic formulations include Apo-Valproic and ratio-Valproic.
Japan
- Tablets – Depakene by Kyowa Hakko Kirin
- Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
- Syrup – Depakene by Kyowa Hakko Kogyo
Europe
In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.
Taiwan
- Tablets (white round tablet) – Depakine by Sanofi Winthrop Industrie (France)
Iran
- Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
- Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)
Israel
Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.
India, Russia and CIS countries
- Valparin Chrono by Sanofi India
- Valprol CR by Intas Pharmaceutical (India)
- Encorate Chrono by Sun Pharmaceutical (India)
- Serven Chrono by Leeven APL Biotech (India)
Uruguay
- Tablets – DI DPA by Megalabs
Brand names of valproate semisodium
- Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil
- Canada – Epival by Abbott Laboratories
- Mexico – Epival and Epival ER (extended release) by Abbott Laboratories
- United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics
- United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics[38]
- India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
- Germany – Ergenyl Chrono by Sanofi-Aventis and generics
- Chile – Valcote and Valcote ER by Abbott Laboratories
- France and other European countries – Depakote
- Peru – Divalprax by AC Farma Laboratories
- China – Diprate OD
Brand names of valproic acid
Branded products include:
- Absenor (Orion Corporation Finland)
- Convulex (G.L. Pharma GmbH Austria)
- Depakene (Abbott Laboratories in US and Canada)[125]
- Depakin (Sanofi S.R.L. Italy)[126]
- Depakine (Sanofi Aventis France)
- Depakine (Sanofi Synthelabo Romania)
- Depalept (Sanofi Aventis Israel)
- Deprakine (Sanofi Aventis Finland)
- Encorate (Sun Pharmaceuticals India)
- Epilim (Sanofi Synthelabo Australia and South Africa)
- Stavzor (Noven Pharmaceuticals Inc.)
- Valcote (Abbott Laboratories Argentina)
- Valpakine (Sanofi Aventis Brazil)
- Orfiril (Desitin Arzneimittel GmbH Norway)
Brand names of sodium valproate
Portugal
- Tablets – Diplexil-R by Bial.
United States
- Intravenous injection – Depacon by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories. (Note: Depakene capsules are valproic acid).
- Depakote tablets are a mixture of sodium valproate and valproic acid.
- Tablets – Eliaxim by Bial.
Australia
New Zealand
All the above formulations are Pharmac-subsidised.[128]
- Epilim by Sanofi-Aventis
UK
- Depakote Tablets (as in USA)
- Tablets – Orlept by Wockhardt and Epilim by Sanofi
- Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
- Syrup – Epilim by Sanofi-Aventis
- Intravenous injection – Epilim Intravenous by Sanofi
- Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
- Enteric-coated tablets – Epilim EC200 by Sanofi is a 200 mg sodium valproate enteric-coated tablet.
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden
- Tablets – Orfiril by Desitin Pharmaceuticals
- Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa
- Syrup – Convulex by Byk Madaus[129]
- Tablets – Epilim by Sanofi-synthelabo
Malaysia
- Tablets – Epilim (200 ENTERIC COATED) by Sanofi-Aventis
- Controlled release tablets – Epilim Chrono (500 CONTROLLED RELEASE) by Sanofi-Aventis[130]
Romania
- Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
- Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
Canada
- Intravenous injection – Epival or Epiject by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories its generic formulations include Apo-Valproic and ratio-Valproic.
Japan
- Tablets – Depakene by Kyowa Hakko Kirin
- Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
- Syrup – Depakene by Kyowa Hakko Kogyo
Europe
In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.
Taiwan
- Tablets (white round tablet) – Depakine by Sanofi Winthrop Industrie (France)
Iran
- Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
- Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)
Israel
Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.
India, Russia and CIS countries
- Valparin Chrono by Sanofi India
- Valprol CR by Intas Pharmaceutical (India)
- Encorate Chrono by Sun Pharmaceutical (India)
- Serven Chrono by Leeven APL Biotech (India)
Uruguay
- Tablets – DI DPA by Megalabs
Portugal
- Tablets – Diplexil-R by Bial.
United States
- Intravenous injection – Depacon by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories. (Note: Depakene capsules are valproic acid).
- Depakote tablets are a mixture of sodium valproate and valproic acid.
- Tablets – Eliaxim by Bial.
Australia
New Zealand
All the above formulations are Pharmac-subsidised.[128]
- Epilim by Sanofi-Aventis
UK
- Depakote Tablets (as in USA)
- Tablets – Orlept by Wockhardt and Epilim by Sanofi
- Oral solution – Orlept Sugar Free by Wockhardt and Epilim by Sanofi
- Syrup – Epilim by Sanofi-Aventis
- Intravenous injection – Epilim Intravenous by Sanofi
- Extended release tablets – Epilim Chrono by Sanofi is a combination of sodium valproate and valproic acid in a 2.3:1 ratio.
- Enteric-coated tablets – Epilim EC200 by Sanofi is a 200 mg sodium valproate enteric-coated tablet.
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
UK only
- Capsules – Episenta prolonged release by Beacon
- Sachets – Episenta prolonged release by Beacon
- Intravenous solution for injection – Episenta solution for injection by Beacon
Germany, Switzerland, Norway, Finland, Sweden
- Tablets – Orfiril by Desitin Pharmaceuticals
- Intravenous injection – Orfiril IV by Desitin Pharmaceuticals
South Africa
- Syrup – Convulex by Byk Madaus[129]
- Tablets – Epilim by Sanofi-synthelabo
Malaysia
- Tablets – Epilim (200 ENTERIC COATED) by Sanofi-Aventis
- Controlled release tablets – Epilim Chrono (500 CONTROLLED RELEASE) by Sanofi-Aventis[130]
Romania
- Companies are SANOFI-AVENTIS FRANCE, GEROT PHARMAZEUTIKA GMBH and DESITIN ARZNEIMITTEL GMBH
- Types are Syrup, Extended release mini tablets, Gastric resistant coated tablets, Gastric resistant soft capsules, Extended release capsules, Extended release tablets and Extended release coated tablets
Canada
- Intravenous injection – Epival or Epiject by Abbott Laboratories.
- Syrup – Depakene by Abbott Laboratories its generic formulations include Apo-Valproic and ratio-Valproic.
Japan
- Tablets – Depakene by Kyowa Hakko Kirin
- Extended release tablets – Depakene-R by Kyowa Hakko Kogyo and Selenica-R by Kowa
- Syrup – Depakene by Kyowa Hakko Kogyo
Europe
In much of Europe, Dépakine and Depakine Chrono (tablets) are equivalent to Epilim and Epilim Chrono above.
Taiwan
- Tablets (white round tablet) – Depakine by Sanofi Winthrop Industrie (France)
Iran
- Tablets – Epival 200 (enteric coated tablet) and Epival 500 (extended release tablet) by Iran Najo
- Slow release tablets – Depakine Chrono by Sanofi Winthrop Industrie (France)
Israel
Depalept and Depalept Chrono (extended release tablets) are equivalent to Epilim and Epilim Chrono above. Manufactured and distributed by Sanofi-Aventis.
India, Russia and CIS countries
- Valparin Chrono by Sanofi India
- Valprol CR by Intas Pharmaceutical (India)
- Encorate Chrono by Sun Pharmaceutical (India)
- Serven Chrono by Leeven APL Biotech (India)
Uruguay
- Tablets – DI DPA by Megalabs
Brand names of valproate semisodium
- Brazil – Depakote by Abbott Laboratories and Torval CR by Torrent do Brasil
- Canada – Epival by Abbott Laboratories
- Mexico – Epival and Epival ER (extended release) by Abbott Laboratories
- United Kingdom – Depakote (for psychiatric conditions) and Epilim (for epilepsy) by Sanofi-Aventis and generics
- United States – Depakote and Depakote ER (extended release) by Abbott Laboratories and generics[38]
- India – Valance and Valance OD by Abbott Healthcare Pvt Ltd, Divalid ER by Linux laboratories Pvt Ltd, Valex ER by Sigmund Promedica, Dicorate by Sun Pharma
- Germany – Ergenyl Chrono by Sanofi-Aventis and generics
- Chile – Valcote and Valcote ER by Abbott Laboratories
- France and other European countries – Depakote
- Peru – Divalprax by AC Farma Laboratories
- China – Diprate OD
Research
A 2023 systematic review of the literature identified only one study in which valproate was evaluated in the treatment of seizures in infants aged 1 to 36 months. In a randomized control trial, valproate alone was found to show poorer outcomes for infants than valproate plus levetiracetam in terms of reduction of seizures, freedom from seizures, daily living ability, quality of life, and cognitive abilities.[131]
References
- Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial Diário Oficial da União, 31 March 2023, retrieved 3 August 2023^
- Product monograph brand safety updates Health Canada, 7 July 2016, retrieved 13 July 2024^
- Depakene, Stavzor (valproic acid) dosing, indications, interactions, adverse effects, and more Medscape Reference, WebMD, retrieved 13 February 2014^
- Valproic Acid The American Society of Health-System Pharmacists, 24 November 2020^
- Valproate banned without the pregnancy prevention programme GOV.UK, retrieved 26 April 2018^
- Drug Safety Update - Valproate medicines (Epilim, Depakote): contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met GOV.UK - Medicines and Healthcare products Regulatory Agency, 24 April 2018, retrieved 17 April 2022^
- Men on sodium valproate told to use contraception BBC News, BBC, retrieved 5 September 2024^
- Valproate and related substances - referral European Medicines Agency (EMA), 2013-10-11, retrieved 2026-01-19^
- Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures European Medicines Agency (EMA), 2024-01-12, retrieved 2026-01-19^
- FDA Information on Valproate^
- Appendix-II www.neurology-jp.org, retrieved 2025-03-05^
- Kusuri-no-Shiori(Drug Information Sheet) www.rad-ar.or.jp, retrieved 2025-03-05^
- Depakote® (divalproex sodium): bipolar mania & epilepsy www.depakote.com, retrieved 2025-03-05^
- Sodium valproate or valproate semisodium: is there a difference in the treatment of bipolar disorder? Psychiatric Bulletin, December 2003^
- Pharmacology of valproate Psychopharmacology Bulletin, 2003^
- Valproic acid pathway: pharmacokinetics and pharmacodynamics Pharmacogenetics and Genomics, April 2013^
- Valproic acid DrugBank, University of Alberta, 29 July 2017, retrieved 30 July 2017^
- Deficient LEF1 expression is associated with lithium resistance and hyperexcitability in neurons derived from bipolar disorder patients Molecular Psychiatry, June 2021^
- The history of epileptic therapy: an account of how medication was developed Parthenon Publ. Group, 1993, retrieved 17 September 2017^
- The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) World Health Organization, 2023^
- Top 300 of 2023 ClinCalc, retrieved 12 August 2025^
- Valproate Drug Usage Statistics, United States, 2013 - 2023 ClinCalc, retrieved 19 August 2025^
- Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy CNS Drugs, 2002^
- Valproate is an effective, well-tolerated drug for treatment of status epilepticus/serial attacks in adults Acta Neurologica Scandinavica. Supplementum, 2007^
- The role of intravenous valproate in convulsive status epilepticus in the future Acta Neurologica Taiwanica, June 2010, retrieved 19 February 2024^
- Depakote ER- divalproex sodium tablet, extended release DailyMed, 24 February 2023, retrieved 19 February 2024^
- Valproate Information U.S. Food and Drug Administration (FDA), retrieved 24 April 2015^
- Valproate for acute mania The Cochrane Database of Systematic Reviews, October 2019^
- Valproate for schizophrenia The Cochrane Database of Systematic Reviews, November 2016, retrieved 27 July 2017^
- Gambling disorder during dopamine replacement treatment in Parkinson's disease: a comprehensive review BioMed Research International, 2014^
- Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease Neurotherapeutics, January 2014^
- Impulsive and compulsive behaviors in Parkinson's disease Annual Review of Clinical Psychology, 2014^
- Valproic acid: medicine used for bipolar disorder, epilepsy and migraine nhs.uk, 2018-09-27, retrieved 2024-11-20^
- Hidden pharmacological activities of valproic acid: A new insight Biomedicine & Pharmacotherapy, October 2021^
- Valpro sodium valproate TGA eBusiness Services, Alphapharm Pty Limited, 16 December 2013, retrieved 14 February 2014^
- Update on MHRA review into safe use of valproate gov.uk/ Compendium, 12 December 2022^
- Depakote 250mg Tablets - Summary of Product Characteristics electronic Medicines Compendium, Sanofi, 28 November 2013, retrieved 18 January 2014^
- Depakote- divalproex sodium tablet, delayed release retrieved 10 November 2015^
- Effects of valproic acid on longitudinal bone growth Journal of Child Neurology, January 2004^
- Inhibition of cartilage growth by the anticonvulsant drugs diphenylhydantoin and sodium valproate British Journal of Experimental Pathology, February 1988^
- Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy Epilepsia, September 2001^
- Could Depakote cause Mydriasis eHealthMe.com, 18 November 2014, retrieved 24 April 2015^
- Polycystic ovary syndrome in women using valproate: a review Gynecological Endocrinology, October 2008^
- Weight change, genetics and antiepileptic drugs Expert Review of Clinical Pharmacology, January 2014^
- The Risk of Thrombocytopenia During Valproic Acid Therapy: A Critical Summary of Available Clinical Data Drugs in R&D, March 2018^
- Valproate Teratogenicity: A Moving Target Obstetrics and Gynecology, September 2022^
- Prenatal Exposure to Valproic Acid Across Various Indications for Use JAMA Network Open, May 2024^
- Valproate (Belvo, Convulex, Depakote, Dyzantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell▼): review by two specialists is required for initiating valproate but not for male patients already taking valproate GOV.UK, retrieved 2026-02-09^
- Valproic Acid Level Medscape, 11 December 2013, retrieved 5 June 2015^
- Free Valproic Acid Assay (Reference – 2013.03.006) Notice of Assessment Canadian Agency for Drugs and Technologies in Health (CADTH) with INESSS's permission, April 2014, retrieved 5 June 2015^
- Valproic acid toxicity: overview and management Journal of Toxicology. Clinical Toxicology, 2002^
- Therapeutic drug monitoring of antiepileptic drugs by use of saliva Therapeutic Drug Monitoring, February 2013^
- Extracorporeal elimination in acute valproic acid poisoning Clinical Toxicology, August 2009^
- R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1622–1626.^
- Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence? Critical Care, October 2005^
- Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy American Journal of Health-System Pharmacy, January 2012^
- Comparison of the effects of L-carnitine, D-carnitine and acetyl-L-carnitine on the neurotoxicity of ammonia Biochemical Pharmacology, July 1993^
- Serum valproate levels with oral contraceptive use Epilepsia, June 2005^
- M-current preservation contributes to anticonvulsant effects of valproic acid The Journal of Clinical Investigation, October 2015^
- Seizure-induced reduction in PIP3 levels contributes to seizure-activity and is rescued by valproic acid Neurobiology of Disease, February 2014^
- Testicular histone hyperacetylation in mice by valproic acid administration affects the next generation by changes in sperm DNA methylation PLOS ONE, 3 September 2023^
- Valproic acid, a molecular lead to multiple regulatory pathways Folia Biologica, 2007, retrieved 13 February 2014^
- Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder Pharmacological Reviews, January 2013^
- Valproate is an anti-androgen and anti-progestin Steroids, December 2005^
- Wyllie's Treatment of Epilepsy: Principles and Practice Lippincott Williams & Wilkins, 17 February 2012^
- Histone acetylation in reproductive organs: Significance of histone deacetylase inhibitors in gene transcription Reproductive Medicine and Biology, June 2005^
- Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy CNS Drugs, 2005^
- Austria-Codex Österreichischer Apothekerverlag, 2021^
- Disposition of valproic acid in maternal, fetal, and newborn sheep. II: metabolism and renal elimination Drug Metabolism and Disposition, July 2000^
- Angewandte Arzneimitteltherapie Springer, 2001^
- Valproate. Accessed 6 August 2021.^
- Valproic Acid DrugBank, University of Alberta, 31 August 2017, retrieved 1 September 2017^
- On the propyl derivatives and decomposition products of ethylacetoacetate Am. Chem. J., 1882^
- [Pharmacodynamic properties of N-dipropylacetic acid] Therapie, 1963^
- Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience CNS Drugs, 2002^
- The history of valproate in clinical neuroscience Psychopharmacology Bulletin, 2003^
- New valproate regulations, informed choice and seizure risk Journal of Neurology, August 2024^
- Sodium valproate Epilepsy Society, 2024-10-01, retrieved 2026-01-19^
- Valproate – reproductive risks GOV.UK, 2025-09-23, retrieved 2026-01-19^
- Secular Trends in the Use of Valproate-Containing Medicines in Women of Childbearing Age in Europe: A Multinational DARWIN EU Network Study Pharmacoepidemiology and Drug Safety, October 2025^
- Jean-Marc Laurent, premier « papa Dépakine » à porter plainte Le Monde, 18 March 2026^
- Un premier « papa Dépakine » saisit la justice pour « mise en danger » de sa fille Le Quotidien du Médecin, 18 March 2026^
- Australian Medicines Handbook The Australian Medicines Handbook Unit Trust, 2013^
- Joint Formulary Committee. British National Formulary (BNF) Pharmaceutical Press, 2013^
- An update on sodium valproate Pharmacotherapy, May–June 1985^
- Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy The New England Journal of Medicine, March 2010^
- Co-Administration of Valproic Acid and Lamotrigine in the Treatment of Refractory Epilepsy (P1.238) Neurology, 6 April 2015, retrieved 4 May 2015^
- O9.06 * Prognostic Relevance and Oncogenic Correlates of Epilepsy in Glioblastoma Patients Neuro-Oncology, 1 September 2014^
- Valproate in acute mania: is our practice evidence based? International Journal of Health Care Quality Assurance, 2012^
- Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis Journal of Affective Disorders, August 2010^
- A review of valproate in psychiatric practice Expert Opinion on Drug Metabolism & Toxicology, May 2009^
- Use of intravenous valproic acid for acute migraine The Annals of Pharmacotherapy, March 2008^
- Valproate for schizophrenia The Cochrane Database of Systematic Reviews, November 2016^
- Valproate preparations for agitation in dementia The Cochrane Database of Systematic Reviews, October 2018^
- Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults The Cochrane Database of Systematic Reviews, October 2011^
- Valproate treatment of acute alcohol hallucinosis: a double-blind, placebo-controlled study Alcohol and Alcoholism, July–August 2008^
- Treatment of intractable hiccups with valproic acid Neurology, November 1981^
- Valproic acid in the treatment of nonepileptic myoclonus Archives of Neurology, July 1982^
- Significance of migrainous features in cluster headache: divalproex responsiveness Headache, July–August 1998^
- Therapy of infantile spasms with valproate: results of a prospective study Epilepsia, September–October 1988^
- Valproic acid and HIV-1 latency: beyond the sound bite Retrovirology, September 2005^
- Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study HIV Medicine, May 2012^
- Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection PLOS ONE, February 2010^
- A phase II study to establish the efficacy and toxicity of sodium valproate in patients with cancer-related neuropathic pain Journal of Pain and Symptom Management, March 2001^
- Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial Annals of Hematology, April 2011^
- Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia Cancer, December 2005^
- The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia Cancer, January 2006^
- Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents Clinical Epigenetics, July 2013^
- A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results Medical Oncology, December 2011^
- A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma British Journal of Cancer, January 2009^
- Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC Clinical Cancer Research, April 2009^
- Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson's disease Parkinsonism & Related Disorders, June 2011^
- Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease Journal of Neurology, February 2013^
- Abbott Laboratories to pay $1.6 billion over illegal marketing of Depakote Washington Post, 7 May 2012, retrieved 27 June 2018^
- Abbott settles marketing lawsuit New York Times, 8 May 2012, retrieved 27 June 2018^
- Valproate reopens critical-period learning of absolute pitch Frontiers in Systems Neuroscience, 2013^
- Learning drugs reawaken grown-up brain's inner child New Scientist, New Scientist Ltd., retrieved 8 May 2021^
- Valproate sodium injection DailyMed, 1 January 2021, retrieved 7 October 2022^
- Valproate sodium injection, solution DailyMed, 29 April 2021, retrieved 7 October 2022^
- The Maudsley Prescribing Guidelines CRC Press, 2009, retrieved 17 September 2017^
- Efficacy, Safety, and Retention Rate of Extended-Release Divalproex Versus Conventional Delayed-Release Divalproex: A Meta-Analysis of Controlled Clinical Trials Frontiers in Pharmacology, 2022-04-05^
- 丙戊酸镁片（湖南湘中） 丁香园·用药助手, retrieved 2025-03-23^
- 丙戊酸镁缓释片（神泰） 丁香园·用药助手, retrieved 2025-03-23^
- Martindale: The Complete Drug Reference Pharmaceutical Press, retrieved 3 March 2018^
- Depakene- valproic acid capsule, liquid filled DailyMed, 19 September 2019, retrieved 14 April 2020^
- Depakin - Banca Dati Farmaci dell'AIFA farmaci.agenziafarmaco.gov.it, Italian Medicines Agency, 6 June 2023, retrieved 6 June 2023^
- Australian product information epilim (sodium valproate) crushable tablets, enteric-coated tablets, syrup, liquid TGA eBS, 15 April 2020, retrieved 15 April 2020^
- Sodium valproate -- Pharmaceutical Schedule Pharmaceutical Management Agency, retrieved 22 June 2014^
- South African Electronic Package Inserts: Convulex retrieved 2 January 2006^
- Malaysian Package Inserts: Epilim retrieved 5 June 2023^
- Management of Infantile Epilepsies effectivehealthcare.ahrq.gov, Agency for Healthcare Research and Quality (US), October 2022, retrieved 12 July 2023^